Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Grande

Showing results (41-50 of 94) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|July 29, 2014
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trialEmilia Pardal, Mónica Coronado, Alejandro Martín, et al.
Haematologica|October 29, 2013
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trialJavier Briones, Silvana Novelli, José A García-Marco, et al.
Haematologica|July 3, 2014
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trialJavier Briones, Silvana Novelli, José A García-Marco, et al.
Medicina Clinica|January 24, 2006
[Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]Blanca Xicoy, Josep M Ribera, Albert Oriol, et al.
Leukemia & Lymphoma|April 29, 2016
Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocolsCristina Motlló, Josep-Maria Ribera, Mireia Morgades, et al.
Haematologica|July 16, 2016
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphomaPier Luigi Zinzani, Lionel Karlin, John Radford, et al.
Cancers|April 14, 2025
Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular LymphomaMaría Poza, Alejandro Martin-Muñoz, Patricia López-Pereira, et al.
British Journal of Haematology|March 5, 2020
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progressionAscensión López-Díaz de Cerio, Ricardo García-Muñoz, Esther Pena, et al.
Chemotherapy|April 22, 2010
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancerJosé-María Roca, Vicente Alonso, Carles Pericay, et al.
European Journal of Haematology|July 17, 2015
Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myelomaFrancisco Javier Peñalver, Julio Delgado, Javier Loscertales, et al.
Pageof 10

Showing results (41-50 of 94) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|July 29, 2014
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trialEmilia Pardal, Mónica Coronado, Alejandro Martín, et al.
Haematologica|October 29, 2013
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trialJavier Briones, Silvana Novelli, José A García-Marco, et al.
Haematologica|July 3, 2014
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trialJavier Briones, Silvana Novelli, José A García-Marco, et al.
Medicina Clinica|January 24, 2006
[Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]Blanca Xicoy, Josep M Ribera, Albert Oriol, et al.
Leukemia & Lymphoma|April 29, 2016
Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocolsCristina Motlló, Josep-Maria Ribera, Mireia Morgades, et al.
Haematologica|July 16, 2016
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphomaPier Luigi Zinzani, Lionel Karlin, John Radford, et al.
Cancers|April 14, 2025
Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular LymphomaMaría Poza, Alejandro Martin-Muñoz, Patricia López-Pereira, et al.
British Journal of Haematology|March 5, 2020
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progressionAscensión López-Díaz de Cerio, Ricardo García-Muñoz, Esther Pena, et al.
Chemotherapy|April 22, 2010
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancerJosé-María Roca, Vicente Alonso, Carles Pericay, et al.
European Journal of Haematology|July 17, 2015
Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myelomaFrancisco Javier Peñalver, Julio Delgado, Javier Loscertales, et al.
Pageof 10